|
Dr. El-Hage is a pharmacologist with extensive FDA experience having worked in the Center for Drug Evaluation and Research (CDER) for over 18 years. Most of her tenure at CDER was spent in the Division of Metabolic and Endocrine Drug Products, where she served as the pharmacology/toxicology supervisor from 2000-2006. Dr El-Hage also concomitantly served as the Associate Director for pharm/tox in the Office of Drug Evaluation I from 2002-2004. Her areas of expertise include preclinical drug development and regulatory toxicology for compounds indicated for the treatment of diabetes, obesity, dyslipidemia, and hormone/metabolic disorders. Dr E-Hage is widely recognized for her expertise in the area of peroxisome proliferator-activated receptor (PPAR) agonist toxicology. She is currently employed as a senior consultant with the Aclairo Pharmaceutical Development Group. | 